Agenus Appoints Robert B. Stein, MD, PhD, as Chief Scientific Officer

  Agenus Appoints Robert B. Stein, MD, PhD, as Chief Scientific Officer

Business Wire

LEXINGTON, Mass. -- January 13, 2014

Agenus Inc. (NASDAQ: AGEN), a biotechnology company developing novel immune
system activating treatments for cancers and infectious diseases, today
announced the appointment of Robert B. Stein, M.D., Ph.D., to the
newly-created position of Chief Scientific Officer (CSO).

Dr. Stein will lead Agenus’ Research, Pre-clinical Development and
Translational Medicine functions and guide the company’s clinical development.
In addition, pending closing, Dr. Stein will play a critical role in leading
the integration of the 4-Antibody acquisition announced today, which includes
the company’s fully human antibody drug discovery and optimization technology
platform and portfolio of immune checkpoint antibody programs.

“Dr. Stein brings over 30 years of experience and accomplishments to the
Agenus leadership team. He is an innovative and experienced executive with
deep, broad knowledge of biology, medicine and pharmaceutical science,” said
Garo Armen, PhD, CEO and chairman of Agenus. “Dr. Stein has had a terrific
record in identifying and developing novel therapeutic modalities. He will
play a key strategic role as we expand into the immune checkpoint field and in
our efforts to establish Agenus as a leader in immuno-oncology. We are
delighted to have him on board.”

“It is now evident that the immune system plays a powerful role in controlling
cancer. Agenus’ roots in immunotherapy combined with 4-Antibody’s
state-of-the-art human monoclonal antibody platform and established immune
checkpoint programs provide a broad spectrum of immunological approaches to
combat cancers and other major diseases,” said Robert Stein, MD, PhD, CSO of
Agenus. “Collaborations with the Ludwig Cancer Research Institute and Memorial
Sloan Kettering Cancer Center provide tremendous advantages in discovering and
developing immune-based medicines for patients battling cancer. I am very
excited to join Agenus during this transformational time.”

Over the course of Dr. Stein’s career he’s played a key role in bringing eight
drugs to the market. He has held a number of progressively responsible senior
management positions including CSO & SVP of Research for Ligand
Pharmaceuticals, EVP of Research & Pre-clinical Development for Dupont Merck,
President and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto and
CEO of KineMed. Dr. Stein spent the early part of his career at Merck, Sharp
and Dohme Research Laboratories. He holds an MD and a PhD in Physiology &
Pharmacology from Duke University.

About Agenus

Agenus Inc. is a biotechnology company developing treatments for cancers and
infectious diseases. The company has multiple immunotherapeutic products based
on strong technology platforms that are advancing through the clinic. Agenus’
technology is further validated through partnerships with major pharmaceutical
companies, with several product candidates in late-stage clinical trials with
corporate partners. Between Agenus and its partners, 23 programs are in
clinical development. For more information, please visit, or
connect with the company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission for the
period ended September 30, 2013. Agenus cautions investors not to place
considerable reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this document, and
Agenus undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their entirety by this
cautionary statement. Agenus’ business is subject to substantial risks and
uncertainties, including those identified above. When evaluating Agenus’
business and securities, investors should give careful consideration to these
risks and uncertainties.


Agenus Inc.
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.